EUVIMEDObjevte EUVIMED
Crossref

Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis

Adam Mead

Future Prescriber · 2012

DOI: 10.1002/fps.100 ↗

At a glance

Journal article in Future Prescriber, 2012. Written by Adam Mead.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease‐related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.

Cite

APA

Mead, A. (2012). Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. https://doi.org/10.1002/fps.100

Vancouver

Mead A. Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. 2012. doi:10.1002/fps.100

BibTeX
@article{Mead2012,
  author = {Mead, Adam},
  title = {Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis},
  journal = {Future Prescriber},
  year = {2012},
  doi = {10.1002/fps.100}
}
Start for free →